Press Releases

December 16

QLT Announces Results of Annual General Meeting of Shareholders

Provides Update on Strategic and Business Review

PDF Format

December 5

QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

PDF Format

December 2

QLT Announces Departure of Chief Financial Officer

PDF Format

October 28

QLT Announces Third Quarter 2014 Results

PDF Format

October 24

QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer Announces 2014 Annual General Meeting Date

PDF Format

October 9

QLT Announces Merger with Auxilium Pharmaceuticals, Inc. Terminates for Superior Proposal

PDF Format

September 22

QLT Provides Further Update on Merger with Auxilium Pharmaceuticals, Inc.

PDF Format

September 17

QLT Provides Update on Merger with Auxilium Pharmaceuticals, Inc.

PDF Format

September 12

QLT Announces Positive Final Results from Phase 1b Retreatment Trial with Oral Synthetic cis-Retinoid (QLT091001) in Subjects with LCA or RP Due to Mutations in RPE65 or LRAT

PDF Format

August 7

QLT Announces Adoption of Advance Notice Policy

PDF Format

August 5

QLT Announces Second Quarter 2014 Results

PDF Format

July 14

QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis due to LRAT or RPE65 Mutations

PDF Format

June 26

Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT

PDF Format

April 30

QLT Announces First Quarter 2014 Results

PDF Format

February 28

QLT Announces Fourth Quarter and Year End 2013 Results

PDF Format

February 27

QLT Announces Positive Preliminary Results from Phase 1b Retreatment Trial of QLT091001 in Subjects with Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65

PDF Format